Pulse Biosciences to present data on NPS technology for treating nBCC
Category: #health  By Pankaj Singh  Date: 2020-01-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pulse Biosciences to present data on NPS technology for treating nBCC

Pulse Biosciences Inc., a bioelectric medicine company, has reportedly announced that it will be presenting its scientific study assessing the clinical and histologic response of NPS™(Nano-Pulse Stimulation™) technology in treating critical cases of nodular nBCC (Basal Cell Carcinoma).

These outcomes are to be presented at the 22nd annual International Master Course on Aging Skin (IMCAS) World Congress, which apparently is the meeting of international experts in plastic surgery, dermatology, and aging science which will meet in Palais des Congrès, Paris, France.

As per sources, the results show the unique ability of NPS technology to remove tumor cells in nBCCs while sparing surrounding healthy tissue. These outcomes will be backed by clinical photos that display favorable cosmetic outcome possible in a short period with reduced potential for scar development as compared to present surgical excision.

The nBCC subtype reported in this study includes 60% of all basal cell carcinomas. Surgical excision is the present standard care of these nodular lesions which can lead to permanent large scars.

Speaking on the data, Dr. Girish Munavalli of Dermatology, Laser & Vein experts of the Carolinas, Charlotte, NC, said that early findings demonstrated promising potential for NPS technology as a novel treatment option for nBCC.

NPS technology has shown similar therapeutic benefit and the added benefit of superior cosmetic results compared to destructive skin cancer treatment modalities, like curettage and excision.

As per Darrin Uecker, CEO and President of Pulse Biosciences, their company is enthusiastic about the impressive results NPS technology is demonstrating in Basal Cell Carcinomas. They are focused on rapidly advancing its development program across multiple clinical applications.

Uecker added that the company’s presence at the IMCAS conference represented its commitment to international commercialization, which aims to extend Pulse’s long-term growth platform and leverage the Nano-Pulse Stimulation Technology to clear malignant and benign lesions.
 

Source Credit - http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-present-data-nano-pulse-stimulation-technology



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

UNMC commences clinical trial of remdesivir for treating COVID-19
UNMC commences clinical trial of remdesivir for treating COVID-19
By Pankaj Singh

A controlled, randomized clinical trial to evaluate the efficacy and safety of the investigational antiviral, remdesivir, in COVID-19 patients has reportedly commenced at the University of Nebraska Medical Center (UNMC...

U.S. to pour $2.5 billion to fight potential coronavirus pandemic
U.S. to pour $2.5 billion to fight potential coronavirus pandemic
By Pankaj Singh

As the coronavirus epidemic continues to scale its way towards the West, several prominent countries across the world have started to develop novel drug solutions for fighting this disease. South Korea recently announc...

ReNeuron shares positive data from Phase 1/2a hRPC stem cell study
ReNeuron shares positive data from Phase 1/2a hRPC stem cell study
By Pankaj Singh

ReNeuron Group plc, a UK based pharmaceutical firm that specializes in cell-based therapeutics, has recently announced encouraging long-term data from its Phase 1/2a clinical study of hRPC stem cell therapy in RP (reti...